Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inhibikase Therapeutics (IKT) Capital Expenditures (2022 - 2025)

Historic Capital Expenditures for Inhibikase Therapeutics (IKT) over the last 2 years, with Q1 2025 value amounting to $13399.0.

  • Inhibikase Therapeutics' Capital Expenditures changed N/A to $13399.0 in Q1 2025 from the same period last year, while for Sep 2025 it was $13399.0, marking a year-over-year change of. This contributed to the annual value of $14238.0 for FY2023, which is 9414.69% down from last year.
  • According to the latest figures from Q1 2025, Inhibikase Therapeutics' Capital Expenditures is $13399.0.
  • In the past 5 years, Inhibikase Therapeutics' Capital Expenditures ranged from a high of $200166.0 in Q3 2022 and a low of $13399.0 during Q1 2025